

Supplementary Table 1. Baseline characteristics of the study participants

| Characteristic | Value |
|-----------------------------------|-------------|
| Age, yr | 51.1 ± 10.6 |
| Female sex | 43 (41.3) |
| Duration of diabetes, yr | 11.7 ± 7.1 |
| Hypertension | 70 (67.3) |
| Dyslipidemia | 101 (97.1) |
| Diabetes complications | |
| Retinopathy | 50 (48.1) |
| Nephropathy | 52 (50.0) |
| Neuropathy | 29 (27.9) |
| Cardiovascular disease | 18 (17.3) |
| Cerebrovascular disease | 2 (1.9) |
| Peripheral vascular disease | 2 (1.9) |
| Heart failure | 2 (1.9) |
| Previous insulin user | 27 (26.0) |
| Use of concomitant diabetes drugs | |
| Metformin | 102 (98.1) |
| Sulfonylurea | 85 (81.7) |
| Thiazolidinedione | 2 (1.9) |
| Insulin | 11 (10.6) |
| Combination sequence | |
| SGLT2 inhibitor first | 48 (46.2) |
| GLP-1RA first | 48 (46.2) |
| Simultaneous addition | 8 (7.7) |
| SGLT2 inhibitor type | |
| Dapagliflozin | 71 (68.3) |
| Empagliflozin | 33 (31.7) |
| Dulaglutide dose, mg | |
| 0.75 | 30 (28.8) |
| 1.5 | 74 (71.2) |

Values are presented as mean ± standard deviation or number (%). SGLT2, sodium-glucose cotransporter 2; GLP-1RA, glucagon-like peptide-1 receptor agonist.